Skip to main content
TipRanks
Go Ultimate75% OFF

BioAge Labs, Inc. (BIOA) AI Stock Analysis

160 Followers
BIOA

BioAge Labs, Inc.

(NASDAQ:BIOA)

Select Model
Rating:45Neutral
Price Target:$5.50▲(5.36% Upside)
Action:reiterated
Date:11/06/26

BIOA scores low primarily due to weak financial performance driven by substantial losses and persistent negative free cash flow, which implies ongoing financing needs. Technicals are also unfavorable with the price below key moving averages and negative MACD. These are partially offset by a strong, low-leverage balance sheet and a positive Phase 2 trial initiation that improves the longer-term outlook.

Positive Factors
Low LeverageVery low leverage gives BioAge financial flexibility while it advances clinical programs and absorbs operating losses. The limited debt burden reduces refinancing pressure and preserves more strategic options than a similarly unprofitable biotech carrying substantial borrowings.
Negative Factors
Heavy Cash BurnDeeply negative operating and free cash flow indicate that BioAge is not yet funding its activities internally. Continued clinical investment therefore depends on its existing resources or external financing, creating pressure to improve operating losses before cash consumption materially weakens flexibility.

BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)

-50%0%50%100%150%200%250%BIOA-36.65%SPY+13.31%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$208.96M
Dividend Yield
―
Average Volume (3M)
733.47K
Price to Earnings (P/E)
-2.2
Beta (1Y)
1.85
Revenue Growth
45.33%
EPS Growth
-20.81%
Country
US
Employees
61
Sector
General
Sector Strength
55
Industry
Biotechnology

BioAge Labs, Inc. Business Overview & Revenue Model

Company Description

BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights...

BioAge Labs, Inc. Financial Statement Overview

Summary

Financial performance is pressured by large ongoing losses and heavy cash burn (TTM net loss ~$107.8M; TTM operating cash flow about -$102.5M and free cash flow about -$103.0M). The balance sheet is a relative strength with very low leverage (debt-to-equity ~0.01) and substantial equity (~$346.4M), but negative returns (TTM ROE ~-29%) indicate continued erosion risk if burn persists.

Income Statement

24Negative

Balance Sheet

72Positive

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022
Income Statement
Total Revenue8.60M8.99M000
Gross Profit8.54M8.99M000
EBITDA-107.38M-79.69M-68.58M-55.90M-39.35M
Net Income-107.80M-80.61M-71.11M-63.85M-39.72M
Balance Sheet
Total Assets367.65M294.89M358.23M25.92M28.43M
Cash, Cash Equivalents and Short-Term Investments283.64M281.10M354.35M21.64M27.64M
Total Debt2.73M5.56M8.70M53.25M2.47M
Total Liabilities21.20M22.84M35.11M199.32M140.99M
Stockholders Equity346.45M272.05M323.13M-173.40M-112.56M
Cash Flow
Free Cash Flow-103.00M-82.35M-51.89M-37.53M-36.28M
Operating Cash Flow-102.52M-81.63M-51.52M-37.36M-36.18M
Investing Cash Flow-218.15M-95.22M-366.00K-266.00K-103.00K
Financing Cash Flow157.78M11.47M381.20M34.94M2.50M

BioAge Labs, Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price5.22

Price Trends

50DMA6.60Negative
100DMA11.67Negative
200DMA15.12Negative

Market Momentum

MACD-0.26Negative
RSI41.92Neutral
STOCH46.49Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOA, the sentiment is Negative. The current price of 5.22 is below the 20-day moving average (MA) of 5.60, below the 50-day MA of 6.60, and below the 200-day MA of 15.12, indicating a bearish trend. The MACD of -0.26 indicates Negative momentum. The RSI at 41.92 is Neutral, neither overbought nor oversold. The STOCH value of 46.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOA.

BioAge Labs, Inc. Risk Analysis

BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

BioAge Labs, Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

BIOA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IRWDIRWD72Outperform$799.61M5.33-93.40%―18.09%403.76%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
DERMDERM50Neutral$122.21M-23.29-16.07%―17.03%49.40%
LFCRLFCR50Neutral$243.36M-3.40381.59%―――
BIOABIOA45Neutral$255.07M-2.18-31.42%―45.33%-20.81%
IXHLIXHL43Neutral$24.72M-2.94-12.40%―-100.00%96.25%

* General Sector Average

Performance Comparison

-100%0%100%200%BIOAIRWDLFCRSXTCDERMIXHLDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
BIOA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
BIOABioAge Labs, Inc.5.22-3.03-36.73%
IRWDIronwood Pharmaceuticals4.851.7455.95%
LFCRLifecore Biomedical, Inc.6.42-1.18-15.59%
SXTCChina Sxt Pharmaceuticals2.99-1919997.01-100.00%
DERMJourney Medical Corporation3.70-4.25-53.46%
IXHLIncannex Healthcare Limited Sponsored ADR1.93-8.56-81.61%

BioAge Labs, Inc. Corporate Events

Business Operations and StrategyProduct-Related Announcements

BioAge Labs initiates Phase 2 trial for BGE-102

Positive
Oct 2, 2026

BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial testing once-daily oral NLRP3 inhibitor BGE-102 in adults with diabetic macular edema. The roughly 180-subject study will compare BGE...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 06, 2026